Given the implication of NLGN1 in neuropsychiatric conditions, as revealed in autism spectrum disorder models [45], assessment of scale-free activity in psychiatric patients is warranted to understand the extent of brain network impairment in these pathological populations, and develop strategies to improve/restore scale-free dynamics. The gene discussed is NLGN1; the disease is autism spectrum disorder.